Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Lionel Aurelien Kankeu Fonkoua (NPI 1144615667)

Field	Value
Entity Type	Individual
Organization	Lionel Aurelien Kankeu Fonkoua
Address	200 1st St Sw
City	Rochester
State	MN
ZIP	55905
Taxonomy	Medical Oncology Physician
NPI Enumerated	April 1, 2015

Payer Source	Total Paid
Medicare	$899.8K
Medicaid	$0

Key Findings

Provider profile and tenure: LIONEL AURELIEN KANKEU FONKOUA is a Medical Oncology Physician based in ROCHESTER, MN with an NPI enumerated on 2015-04-01 (~11 years ago). The billing mix and code selection are consistent with a community-based oncology practice that has been operating for about a decade and billing Medicare directly for infusion services.

Medicare dominance and absent Medicaid billing: This provider reports Total Medicare revenue of $899.8K and has no Medicaid billing on file, making the practice effectively single-payer in the public programs data; there is no Medicaid activity to evaluate for in-state payer mix or volume comparisons. This concentration means public-pay exposure is driven entirely by Medicare reimbursement patterns in the available dataset.

Revenue concentration in a few immunotherapy codes: The top three Medicare codes (J9271, J9144, J9299) account for 86.1% of this provider's total Medicare revenue, indicating a heavy concentration in a small number of high-value biologic/immunotherapy products. Specifically, J9271 accounts for $425.7K (47.6%), J9144 for $226.6K (25.3%), and J9299 for $117.1K (13.1%) of Medicare revenue, highlighting dependence on these agents for the practice’s financial performance.

Clinical/service-line implications: The dominant codes are drug administration entries for pembrolizumab (J9271), daratumumab (J9144), and nivolumab (J9299), supported by chemotherapy administration codes (96413, G0498, 96417) in smaller volumes. This mix indicates an outpatient infusion model focused on monoclonal antibody and checkpoint inhibitor therapy rather than high-volume, traditional cytotoxic chemotherapy regimens, suggesting workflow, staffing, and infusion-capacity requirements aligned with immunotherapy delivery.

Volume and competitive standing for top drugs: Although J9271 generates the largest share of revenue ($425.7K), the provider’s national rank for that code is #1202 of 1841 (35th percentile; typical, unremarkable volume for this code), which signals a meaningful absolute revenue contribution but only a modest national footprint. J9144 ranks #420 of 615 (32th percentile; typical, unremarkable volume for this code) and J9299 ranks #487 of 505 (4th percentile; typical, unremarkable volume for this code), indicating relatively low national standing for daratumumab and especially for nivolumab despite their contribution to the provider’s revenue mix.

Evidence of limited activity in biosimilars and supportive agents: Biosimilar codes Q5119 ($19.5K, 2.2%) and Q5118 ($19.1K, 2.1%) appear in the top-25 but rank low nationally (#322 of 335 and #155 of 161 respectively, both noted as 4th percentile; typical, unremarkable volume for this code), suggesting limited use or market presence in those specific biosimilars relative to peers. Supportive and administration-level codes (96413: 238 claims, $25.2K; G0498: 23 claims, $4.9K) represent a small share of revenue compared with the high-cost drugs, reinforcing the drug-driven nature of revenue rather than high-frequency office E/M or infusion time charges.

Payment profile and operational sensitivity: High claim counts at moderate per-claim payments drive overall revenue — for example J9271 shows 9.9K claims at $43 avg paid/claim producing $425.7K in revenue, and J9144 shows 6.1K claims at $37 avg paid/claim producing $226.6K. Because 86.1% of Medicare revenue is concentrated in three immunotherapy/antibody agents, the practice’s financial performance is sensitive to changes in utilization patterns, reimbursement policy, or formulary placement for those agents, with little Medicaid offset to diversify public-pay risk.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

41 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	9,900	$40	$425.7K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	6,120	$40	$226.6K
J9299	Injection, nivolumab, 1 mg	4,880	$20	$117.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	240	$110	$25.2K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	930	$20	$19.5K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	830	$20	$19.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	120	$100	$11.7K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	70	$140	$9.7K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	30	$170	$5.5K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	90	$60	$5.3K

Showing 1–10 of 41

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 41 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Lionel Aurelien Kankeu Fonkoua — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

41 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	21	70	7,200	$40	$323.3K
J9144	8	50	3,780	$40	$163.7K
J9299	13	20	5,240	$20	$159.4K
Q5118	14	20	990	$20	$33.7K
Q5119	25	30	1,380	$20	$29.5K
J9217	45	80	80	$130	$17.1K
96413	33	230	70	$100	$11.5K
99214	2,930	10,100	70	$80	$8.1K
G0498	29	50	30	$200	$5.7K
J3490	16	70	40	$110	$5K

Showing 1–10 of 41

Related Providers

Other providers that share a Tax Identification Number (TIN) with Lionel Aurelien Kankeu Fonkoua, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mayo Clinic	MN	Multi-Specialty Clinic/Center	$0	$74.3M
Mayo Clinic	MN	Clinical Medical Laboratory	$12.2M	$15.2M
Mayo Clinic Health System-southeast Minnesota Region	MN	Multi-Specialty Clinic/Center	$0	$13.7M
Mayo Clinic Hospital-rochester	MN	General Acute Care Hospital	$0	$11.5M
Robert Jacobson	MN	Pediatrics Physician	$975.6K	$0
Mojun Zhu	AZ	Hematology & Oncology Physician	$947.4K	$0
Timothy Hobday	MN	Medical Oncology Physician	$931.3K	$0
Matthew Block	MN	Medical Oncology Physician	$820.5K	$0
Ron Smith	MN	Radiation Oncology Physician	$806K	$0
Julian Molina	MN	Medical Oncology Physician	$773.4K	$0

Nearby Providers

Other providers in the same ZIP code as Lionel Aurelien Kankeu Fonkoua, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mayo Collaborative Services, Inc	MN	Clinical Medical Laboratory	$6.5M	$39.2M
Mayo Clinic	MN	Multi-Specialty Clinic/Center	$0	$10.9M
Mayo Foundation For Medical Education & Research	MN	Durable Medical Equipment & Medical Supplies	$9.3K	$2.8M
Vidhu Kaushik	MN	Clinical Pathology/Laboratory Medicine Physician	$59.6K	$1.9M
Roberto Leon Ferre	MN	Medical Oncology Physician	$1.3M	$0
Peter Noseworthy	MN	Cardiovascular Disease Physician	$1.1M	$0
Daniel Childs	MN	Medical Oncology Physician	$1.1M	$0
Brittany Siontis	MN	Medical Oncology Physician	$960.6K	$0
Sani Kizilbash	MN	Medical Oncology Physician	$946.7K	$0
Katharine Price	MN	Medical Oncology Physician	$832.6K	$0

Lionel Aurelien Kankeu Fonkoua — Billing Profile & Reimbursement Data

Sign up for Lionel Aurelien Kankeu Fonkoua — Billing Profile & Reimbursement Data policy alerts

Lionel Aurelien Kankeu Fonkoua — Billing Profile & Reimbursement Data

Sign up for Lionel Aurelien Kankeu Fonkoua — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References